The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
SUMMARY
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising
new platform used by two leading vaccines against COVID-19. Clinical trials
and ongoing vaccinations present with varying degrees of protection levels
and side effects. However, the drivers of the reported side effects remain poorly
defined. Here we present evidence that Acuitas’ LNPs used in preclinical nucleo-
side-modified mRNA vaccine studies are highly inflammatory in mice. Intradermal
and intramuscular injection of these LNPs led to rapid and robust inflammatory
responses, characterized by massive neutrophil infiltration, activation of diverse
inflammatory pathways, and production of various inflammatory cytokines and
chemokines. The same dose of LNP delivered intranasally led to similar inflamma-
tory responses in the lung and resulted in a high mortality rate, with mechanism
unresolved. Thus, the mRNA-LNP platforms’ potency in supporting the induction
of adaptive immune responses and the observed side effects may stem from the
LNPs’ highly inflammatory nature
@bonifartius @iron_bug I can get to the PDF no problem. Censored in some countries? I'm in Sweden.